| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | OPNT | Common Stock | Options Exercise | $14,750 | +1,475 | +25% | $10.00 | 7,475 | 07 Sep 2021 | Direct | |
| transaction | OPNT | Common Stock | Sale | $14,796 | -822 | -11% | $18.00 | 6,653 | 07 Sep 2021 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | OPNT | Stock Option (right to buy) | Options Exercise | $0 | -1,475 | -18% | $0.000000 | 6,859 | 07 Sep 2021 | Common Stock | 1,475 | $10.00 | Direct | F3, F4 |
| Id | Content |
|---|---|
| F1 | The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. |
| F2 | The shares were sold to cover the $10 exercise price of the vested stock options. The net shares of 653, after selling to cover the exercise price, will be held by the Reporting Person. |
| F3 | The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. |
| F4 | On November 4, 2016, the reporting person was granted an option to purchase 35,000 shares of Common Stock. The options vest as follows: (i) 11,667 share upon the up listing of the Issuer to The NASDAQ Stock Market (which occurred on August 29, 2017); (ii) 11,667 shares upon the cumulative funding of the Issuer in excess of $5,000,000 by institutional investors, commencing May 5, 2016 (which performance criteria was met on December 13, 2016); and (iii) 11,666 shares upon the first submission of a New Drug Application ("NDA") to the FDA for one of Issuer's products by either the Issuer or an Issuer licensee. |